Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,209,436 papers from all fields of science
Search
Sign In
Create Free Account
apomab
A fully human monoclonal antibody directed against human death receptor 5 (DR5; TRAIL-R2; TNFRSF10B) with potential pro-apoptotic and antineoplastic…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Inhibition of Cell Proliferation
Positive Regulation of Apoptosis
TNFRSF10B protein, human
antigen binding
Broader (1)
Monoclonal Antibodies
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Monoclonal Antibody Relates to Apoptotic Cell Clearance Postchemotherapy and Tumor-Selective Targeting with the La-Specific DAB 4
F. Al-Ejeh
,
A. H. Staudacher
,
+5 authors
M. Brown
2014
Corpus ID: 207886065
Published online: March 27, 2014. 2014;55:772-779. J Nucl Med. Rodney J. Hicks and Michael P. Brown Fares Al-Ejeh, Alexander H…
Expand
2011
2011
Abstract LB-232: APG350, a dimerized single chain TRAIL receptor agonist with enhanced functional properties
C. Gieffers
,
M. Kluge
,
+4 authors
F. Harald
2011
Corpus ID: 58506801
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL TRAIL (Apo2L) is a member of the Tumor Necrosis Factor…
Expand
Highly Cited
2008
Highly Cited
2008
Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival
Hongkui Jin
,
Renhui Yang
,
+9 authors
A. Ashkenazi
Clinical Cancer Research
2008
Corpus ID: 14208328
Purpose: Apomab is a fully human monoclonal antibody that induces programmed cell death through the proapoptotic receptor DR5 in…
Expand
Review
2008
Review
2008
Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.
D. Camidge
Expert Opinion on Biological Therapy
2008
Corpus ID: 34410664
BACKGROUND Apomab is a pro-apoptotic anticancer agonist monoclonal antibody against Death receptor 5 (DR5)/TNF-related apoptosis…
Expand
2008
2008
Identification of potentially predictive biomarkers for tumor sensitivity to proapoptotic receptor agonists
A. Ashkenazi
,
K. Wagner
,
E. Punnnoose
,
D. Lawrence
,
R. Pitti
,
L. Amler
2008
Corpus ID: 81592483
14505 Background: Apo2L/TRAIL selectively stimulates cancer-cell death through the proapoptotic receptors DR4 and DR5. Endogenous…
Expand
2007
2007
A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer
D. Camidge
,
R. Herbst
,
+6 authors
D. Mendelson
2007
Corpus ID: 73932006
3582 Background: Apomab, a fully human affinity-matured IgG1 monoclonal antibody, is a DR5 pro-apoptotic receptor agonist that…
Expand
2007
2007
Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin’s lymphoma
D. Daniel
,
Becky Yang
,
+4 authors
A. Ashkenazi
2007
Corpus ID: 83557552
B32 Activation of the pro-apoptotic receptor DR5 triggers apoptosis through the cell-extrinsic pathway. We have generated fully…
Expand
2007
2007
Gateways to clinical trials.
M. Bayés
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2007
Corpus ID: 44468285
(-)-Epigallocatechin gallate, [188Re]-P2045, 12B75, 89-12; Abacavir sulfate/lamivudine, Abatacept, Abiraterone acetate, ABT-869…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE